Department of Radiation Oncology.
Department of Medicine, and.
Am J Respir Cell Mol Biol. 2022 May;66(5):497-509. doi: 10.1165/rcmb.2021-0357OC.
The paucity of therapeutic strategies to reduce the severity of radiation-induced lung fibrosis (RILF), a life-threatening complication of intended or accidental ionizing radiation exposure, is a serious unmet need. We evaluated the contribution of eNAMPT (extracellular nicotinamide phosphoribosyltransferase), a damage-associated molecular pattern (DAMP) protein and TLR4 (Toll-like receptor 4) ligand, to the severity of whole-thorax lung irradiation (WTLI)-induced RILF. Wild-type (WT) and heterozygous C57BL6 mice and nonhuman primates (NHPs, ) were exposed to a single WTLI dose (9.8 or 10.7 Gy for NHPs, 20 Gy for mice). WT mice received IgG (control) or an eNAMPT-neutralizing polyclonal or monoclonal antibody (mAb) intraperitoneally 4 hours after WTLI and weekly thereafter. At 8-12 weeks after WTLI, NAMPT expression was assessed by immunohistochemistry, biochemistry, and plasma biomarker studies. RILF severity was determined by BAL protein/cells, hematoxylin and eosin, and trichrome blue staining and soluble collagen assays. RNA sequencing and bioinformatic analyses identified differentially expressed lung tissue genes/pathways. NAMPT lung tissue expression was increased in both WTLI-exposed WT mice and NHPs. mice and eNAMPT polyclonal antibody/mAb-treated mice exhibited significantly attenuated WTLI-mediated lung fibrosis with reduced: ) NAMPT and trichrome blue staining; ) dysregulated lung tissue expression of smooth muscle actin, p-SMAD2/p-SMAD1/5/9, TGF-β, TSP1 (thrombospondin-1), NOX4, IL-1β, and NRF2; ) plasma eNAMPT and IL-1β concentrations; and ) soluble collagen. Multiple WTLI-induced dysregulated differentially expressed lung tissue genes/pathways with known tissue fibrosis involvement were each rectified in mice receiving eNAMPT mAbs.The eNAMPT/TLR4 inflammatory network is essentially involved in radiation pathobiology, with eNAMPT neutralization an effective therapeutic strategy to reduce RILF severity.
缺乏治疗策略来减轻放射性肺纤维化 (RILF) 的严重程度,这是一种危及生命的并发症,由预期或意外的电离辐射暴露引起,这是一个严重的未满足的需求。我们评估了细胞外烟酰胺磷酸核糖转移酶 (eNAMPT,一种损伤相关分子模式 (DAMP) 蛋白和 TLR4 (Toll 样受体 4) 配体) 对全胸肺照射 (WTLI) 诱导的 RILF 严重程度的贡献。野生型 (WT) 和杂合 C57BL6 小鼠和非人灵长类动物 (NHPs, ) 接受单次 WTLI 剂量 (NHPs 为 9.8 或 10.7 Gy,小鼠为 20 Gy)。WT 小鼠在 WTLI 后 4 小时内接受 IgG (对照) 或 eNAMPT 中和多克隆或单克隆抗体 (mAb) 腹腔内注射,此后每周一次。在 WTLI 后 8-12 周,通过免疫组织化学、生物化学和血浆生物标志物研究评估 NAMPT 表达。通过 BAL 蛋白/细胞、苏木精和伊红以及三原色蓝染色和可溶性胶原测定来确定 RILF 严重程度。RNA 测序和生物信息学分析鉴定了差异表达的肺组织基因/途径。WTLI 暴露的 WT 小鼠和 NHPs 的肺组织中 NAMPT 表达增加。和 eNAMPT 多克隆抗体/mAb 治疗的小鼠表现出明显减轻的 WTLI 介导的肺纤维化,具有降低的:)NAMPT 和三原色蓝染色;)肺组织中平滑肌肌动蛋白、p-SMAD2/p-SMAD1/5/9、TGF-β、TSP1(血栓素-1)、NOX4、IL-1β 和 NRF2 的失调表达;)血浆 eNAMPT 和 IL-1β 浓度;和)可溶性胶原。接受 eNAMPT mAb 的小鼠中,多种 WTLI 诱导的失调差异表达的肺组织基因/途径,这些途径均与组织纤维化有关,每个途径都得到了纠正。eNAMPT/TLR4 炎症网络本质上参与了放射生物学,eNAMPT 中和是一种有效的治疗策略,可以减轻 RILF 的严重程度。